Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors

IDH1/2-inhibitor–based combinations conferred significant clinical responses in patients with IDH1/2-mutated post–MPN AML. Complete remission was achieved in 3/7 patients (1 attaining MRD–) with new IDH1/2-mutated post–MPN AML treated with IDH1/2-i combinations.

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood Adv
Egile Nagusiak: Chifotides, Helen T., Masarova, Lucia, Alfayez, Mansour, Daver, Naval, Alvarado, Yesid, Jabbour, Elias, Konopleva, Marina, Kantarjian, Hagop M., Patel, Keyur P., DiNardo, Courtney D., Verstovsek, Srdan
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2020
Gaiak:
Stimulus Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7656917/
https://ncbi.nlm.nih.gov/pubmed/33112940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001528
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak